Diagnosis of interstitial lung diseases: from Averill A. Liebow to artificial intelligence

키워드

참고문헌 (69)

1. Liebow A, "Frontiers of pulmonary radiology", pp.102~141 (1969), Grune and Stratton
2. Katzenstein AL, "Idiopathic pulmonary fibrosis : clinical relevance of pathologic classification", Am J Respir Crit Care Med, 157, pp.1301~1315 (1998)
3. American Thoracic Society, "Idiopathic pulmonary fibrosis : diagnosis and treatment. International consensus statement. American Thoracic Society(ATS), and the European Respiratory Society(ERS)", Am J Respir Crit Care Med, 161, pp.646~664 (2000)
4. American Thoracic Society, "American Thoracic Society", European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. This joint statement of the American Thoracic Society(ATS), and the European Respiratory Society(ERS)was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001, 2002, pp.165, 277~304
5. Travis WD, "An official American Thoracic Society", European Respiratory Society statement : Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias, 2013, pp.188, 733~748
6. Raghu G, "An official ATS", ERS, ALAT statement : idiopathic pulmonary fibrosis : evidence-based guidelines for diagnosis and management, pp.Am J Respir Crit Care Med, 2011[DOI]
7. Raghu G, "Idiopathic pulmonary fibrosis(an update)and progressive pulmonary fibrosis in adults : an official ATS", ERS, ALAT clinical practice guideline, pp.Am J Respir Crit Care Med, 2022[DOI]
8. Kim SY, "Classification of usual interstitial pneumonia in patients with interstitial lung disease : assessment of a machine learning approach using high-dimensional transcriptional data", Lancet Respir Med, 3, pp.473~482 (2015)
9. Raghu G, "Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples : a prospective validation study", Lancet Respir Med, 7, pp.487~496 (2019)
10. Collard HR, "Acute exacerbations of idiopathic pulmonary fibrosis", Am J Respir Crit Care Med, 176, pp.636~643 (2007)
11. Azuma A, "Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis", Am J Respir Crit Care Med, 171, pp.1040~1047 (2005)
12. Taniguchi H, "Pirfenidone in idiopathic pulmonary fibrosis", Eur Respir J, 35, pp.821~829 (2010)
13. Richeldi L, "Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis", N Engl J Med, 365, pp.1079~1087 (2011)
14. Richeldi L, "Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis", N Engl J Med, 370, pp.2071~2082 (2014)
15. Raghu G, "An official ATS", ERS, ALAT clinical practice guideline : treatment of idiopathic pulmonary fibrosis : an update of the 2011 clinical practice guideline, pp.Am J Respir Crit Care Med, 2015[DOI]
16. Raghu G, "Diagnosis of idiopathic pulmonary fibrosis : an official ATS", ERS, ALAT clinical practice guideline, pp.Am J Respir Crit Care Med, 2018[DOI]
17. Selman M, "Usual interstitial pneumonia as a stand-alone diagnostic entity : the case for a paradigm shift?", Lancet Respir Med, 11, pp.188~196 (2023)
18. Hambly N, "Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry", Eur Respir J, 60, pp.2102571~ (2022)
19. Hozumi H, "Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease : a retrospective case control study", BMJ Open, 3, pp.e003132~ (2013)
20. Kang J, "Acute exacerbation of fibrotic hypersensitivity pneumonitis : incidence and outcomes", Respir Res, 22, pp.152~ (2021)
21. Adegunsoye A, "Computed tomography honeycombing identifies a progressive fibrotic phenotype with increased mortality across diverse interstitial lung diseases", Ann Am Thorac Soc, 16, pp.580~588 (2019)
22. Wijsenbeek M, "Spectrum of fibrotic lung diseases", N Engl J Med, 383, pp.958~968 (2020)
23. Cottin V, "Fibrosing interstitial lung diseases : knowns and unknowns", Eur Respir Rev, 28, pp.180100~ (2019)
24. Brown KK, "The natural history of progressive fibrosing interstitial lung diseases", Eur Respir J, 55, pp.2000085~ (2020)
25. Nasser M, "Progressive fibrosing interstitial lung disease : a clinical cohort(the PROGRESS study)", Eur Respir J, 57, pp.2002718~ (2021)
26. Flaherty KR, "Design of the PF-ILD trial : a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease", BMJ Open Respir Res, 4, pp.e000212~ (2017)
27. Flaherty KR, "Nintedanib in progressive fibrosing interstitial lung diseases", N Engl J Med, 381, pp.1718~1727 (2019)
28. Maher TM, "Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease : a double-blind, randomised, placebo-controlled, phase 2 trial", Lancet Respir Med, 8, pp.147~157 (2020)
29. Behr J, "Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis(RELIEF) : a double-blind, randomised, placebocontrolled, phase 2b trial", Lancet Respir Med, 9, pp.476~486 (2021)
30. Wells AU, "Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial : a randomised, double-blind, placebo-controlled, parallel-group trial", Lancet Respir Med, 8, pp.453~460 (2020)
31. Matteson EL, "Nintedanib in patients with autoimmune disease-related progressive fibrosing interstitial lung diseases : subgroup analysis of the INBUILD trial", Arthritis Rheumatol, 74, pp.1039~1047 (2022)
32. "Beitr Pathol Anat", 1907, 496~517
33. Marshall RP, "Adult familial cryptogenic fibrosing alveolitis in the United Kingdom", Thorax, 55, pp.143~146 (2000)
34. Hodgson U, "Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis : evidence of founder effect among multiplex families in Finland", Thorax, 57, pp.338~342 (2002)
35. Barlo NP, "Surfactant protein-D predicts survival in patients with idiopathic pulmonary fibrosis", Sarcoidosis Vasc Diffuse Lung Dis, 26, pp.155~161 (2009)
36. Garcia-Sancho C, "Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis", Respir Med, 105, pp.1902~1907 (2011)
37. Loyd JE, "Pulmonary fibrosis in families", Am J Respir Cell Mol Biol, 29, pp.S47~S50 (2003)
38. Fernandez BA, "A Newfoundland cohort of familial and sporadic idiopathic pulmonary fibrosis patients : clinical and genetic features", Respir Res, 13, pp.64~ (2012)
39. Ley B, "The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis : an observational cohort-control study", Lancet Respir Med, 5, pp.639~647 (2017)
40. Newton CA, "Telomere length and genetic variant associations with interstitial lung disease progression and survival", Eur Respir J, 53, pp.1801641~ (2019)
41. Cutting CC, "Family history of pulmonary fibrosis predicts worse survival in patients with interstitial lung disease", Chest, 159, pp.1913~1921 (2021)
42. Steele MP, "Clinical and pathologic features of familial interstitial pneumonia", Am J Respir Crit Care Med, 172, pp.1146~1152 (2005)
43. Newton CA, "Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive", Eur Respir J, 48, pp.1710~1720 (2016)
44. Mathai SK, "MUC5B variant is associated with visually and quantitatively detected preclinical pulmonary fibrosis", Thorax, 74, pp.1131~1139 (2019)
45. Hunninghake GM, "Interstitial lung disease in relatives of patients with pulmonary fibrosis", Am J Respir Crit Care Med, 201, pp.1240~1248 (2020)
46. Salisbury ML, "Development and progression of radiologic abnormalities in individuals at risk for familial interstitial lung disease", Am J Respir Crit Care Med, 201, pp.1230~1239 (2020)
47. Mathai SK, "Pulmonary fibrosis in the era of stratified medicine", Thorax, 71, pp.1154~1160 (2016)
48. Seibold MA, "A common MUC5B promoter polymorphism and pulmonary fibrosis", N Engl J Med, 364, pp.1503~1512 (2011)
49. van Moorsel CH, "Genetic disorders of the surfactant system : focus on adult disease", Eur Respir Rev, 30, pp.200085~ (2021)
50. Nogee LM, "A mutation in the surfactant protein C gene associated with familial interstitial lung disease", N Engl J Med, 344, pp.573~579 (2001)
51. Thomas AQ, "Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred", Am J Respir Crit Care Med, 165, pp.1322~1328 (2002)
52. van Moorsel CH, "SFTPA2mutations in familial and sporadic idiopathic interstitial pneumonia", Am J Respir Crit Care Med, 192, pp.1249~1252 (2015)
53. Armanios MY, "Telomerase mutations in families with idiopathic pulmonary fibrosis", N Engl J Med, 356, pp.1317~1326 (2007)
54. Tsakiri KD, "Adult-onset pulmonary fibrosis caused by mutations in telomerase", Proc Natl Acad Sci U S A, 104, pp.7552~7557 (2007)
55. Armanios M, "Telomerase and idiopathic pulmonary fibrosis", Mutat Res, 730, pp.52~58 (2012)
56. Savage SA, "Dyskeratosis congenita", Hematol Oncol Clin North Am, 23, pp.215~231 (2009)
57. Diaz de Leon A, "Subclinical lung disease, macrocytosis, and premature graying in kindreds with telomerase(TERT)mutations", Chest, 140, pp.753~763 (2011)
58. Borie R, "Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis", Eur Respir J, 48, pp.1721~1731 (2016)
59. Juge PA, "Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis", Eur Respir J, 49, pp.1602314~ (2017)
60. Petrovski S, "An exome sequencing study to assess the role of rare genetic variation in pulmonary fibrosis", Am J Respir Crit Care Med, 196, pp.82~93 (2017)
61. Dressen A, "Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis : a candidate gene sequencing study", Lancet Respir Med, 6, pp.603~614 (2018)
62. Ley B, "Rare protein-altering telomere-related gene variants in patients with chronic hypersensitivity pneumonitis", Am J Respir Crit Care Med, 200, pp.1154~1163 (2019)
63. Cronkhite JT, "Telomere shortening in familial and sporadic pulmonary fibrosis", Am J Respir Crit Care Med, 178, pp.729~737 (2008)
64. Leslie KO, "Familial idiopathic interstitial pneumonia : histopathology and survival in 30 patients", Arch Pathol Lab Med, 136, pp.1366~1376 (2012)
65. Viswanathan VS, "The state of the art for artificial intelligence in lung digital pathology", J Pathol, 257, pp.413~429 (2022)
66. Makela K, "Artificial intelligence identifies inflammation and confirms fibroblast foci as prognostic tissue biomarkers in idiopathic pulmonary fibrosis", Hum Pathol, 107, pp.58~68 (2021)
67. Uegami W, "MIXTURE of human expertise and deep learning-developing an explainable model for predicting pathological diagnosis and survival in patients with interstitial lung disease", Mod Pathol, 35, pp.1083~1091 (2022)
68. Testa LC, "Automated digital quantification of pulmonary fibrosis in human histopathology specimens", Front Med (Lausanne), 8, pp.607720~ (2021)
69. Ashcroft T, "Simple method of estimating severity of pulmonary fibrosis on a numerical scale", J Clin Pathol, 41, pp.467~470 (1988)

관련 논문AI추천